Breaking Down Amicus Therapeutics, Inc. (FOLD) Financial Health: Key Insights for Investors

Are you tracking Amicus Therapeutics' (FOLD) financial trajectory and wondering if it's a sound investment? In 2024, the company reported a total revenue of $528.3 million, marking a significant 33% increase year-over-year. With key products like Galafold generating $458.1 million in net product sales and Pombiliti + Opfolda reaching $70.2 million, how will these figures shape future growth? The company anticipates revenue growth of 17% to 24% in 2025, and projects surpassing $1 billion in total sales by 2028. Dive in to explore the key insights that will help you assess Amicus Therapeutics' financial health and potential.

Amicus Therapeutics, Inc. (FOLD) Revenue Analysis

Amicus Therapeutics, Inc. (FOLD) generates revenue primarily through the sales of its commercial products. The company focuses on developing and delivering therapies for rare metabolic diseases.

Here's a breakdown of what to consider regarding Amicus Therapeutics, Inc. (FOLD)'s revenue streams:

• Primary Revenue Sources: The main source of revenue for Amicus Therapeutics, Inc. (FOLD) is the sale of Galafold, a therapy for Fabry disease.
• Geographic Revenue: Amicus Therapeutics, Inc. (FOLD) generates revenue from North America, Europe and Rest of World.

When evaluating Amicus Therapeutics, Inc. (FOLD)'s financial health, it's crucial to consider these elements. For additional insights into the company's strategic direction, you might find this resource helpful: Mission Statement, Vision, & Core Values of Amicus Therapeutics, Inc. (FOLD).

Amicus Therapeutics, Inc. (FOLD) Profitability Metrics

Analyzing Amicus Therapeutics, Inc. (FOLD) profitability involves examining several key metrics that provide insights into the company's financial health and operational efficiency. These metrics include gross profit, operating profit, and net profit margins, as well as trends in profitability over time and comparisons with industry averages.

As of the fiscal year 2024, Amicus Therapeutics, Inc. (FOLD) presents a complex financial picture, particularly regarding profitability. It's important to note that pharmaceutical companies, especially those focused on research and development, may exhibit unique profitability profiles compared to other industries. Here’s a breakdown of key areas:

Gross Profit:

Gross profit is a critical indicator of how efficiently a company manages its production costs and pricing strategies. For Amicus Therapeutics, monitoring the gross profit trend helps in understanding the direct profitability from its product sales. According to the latest available information, Amicus Therapeutics reported $496.6 million total revenues in 2024.

Operating Profit:

Operating profit provides a clearer picture of profitability by including operating expenses such as research and development (R&D) and selling, general, and administrative (SG&A) costs. Analyzing Amicus Therapeutics' operating profit helps to understand how well the company manages its operational costs in relation to its revenue. The company's operating loss for 2024 was $329.1 million.

Net Profit Margins:

Net profit margin is the percentage of revenue remaining after all expenses, including taxes and interest, have been deducted. This metric offers insight into the overall profitability of the company. In 2024, Amicus Therapeutics' net loss was $333.7 million, or ($1.17) per share.

Trends in Profitability Over Time:

Examining profitability trends over several years is essential to understand the sustainability and growth potential of Amicus Therapeutics. Analyzing historical data reveals whether the company is improving its efficiency, reducing costs, and increasing revenue. Amicus Therapeutics' total revenues have shown substantial growth, increasing from $305.9 million in 2021 to $496.6 million in 2024.

Analysis of Operational Efficiency:

Operational efficiency is crucial for maintaining and improving profitability. Effective cost management and favorable gross margin trends are indicators of a company's ability to control expenses and maximize profits. Amicus Therapeutics' cost of goods sold in 2024 was $91.1 million, resulting in a gross profit of $405.5 million.

Comparison of Profitability Ratios with Industry Averages:

Benchmarking Amicus Therapeutics' profitability ratios against industry averages provides valuable context. This comparison helps investors assess whether the company is performing above or below its peers, which can influence investment decisions. However, direct comparisons can be challenging due to the unique nature of the biotechnology industry and the variability in R&D expenditures.

For additional insights, you might find this resource helpful: Breaking Down Amicus Therapeutics, Inc. (FOLD) Financial Health: Key Insights for Investors

Amicus Therapeutics, Inc. (FOLD) Debt vs. Equity Structure

Amicus Therapeutics, Inc. (FOLD) strategically uses a mix of debt and equity to fund its growth and operational needs. Understanding the specifics of their debt levels, debt-to-equity ratio, and any recent financing activities offers key insights into the company's financial strategy and risk profile.

As of the fiscal year 2024, a detailed overview of Amicus Therapeutics, Inc. (FOLD)'s debt levels is essential for investors. While specific figures for 2024 are not available, examining the latest available data helps provide a perspective on their financial structure.

Here's a breakdown of what to consider regarding Amicus Therapeutics, Inc. (FOLD)'s debt:

• Long-Term Debt: This includes obligations due beyond one year, which can consist of bonds, loans, and other financial instruments.
• Short-Term Debt: This encompasses liabilities due within one year, such as short-term loans or the current portion of long-term debt.

The debt-to-equity ratio is a critical metric for evaluating Amicus Therapeutics, Inc. (FOLD)'s financial leverage. It indicates the proportion of debt and equity the company uses to finance its assets. A higher ratio suggests greater financial risk, as the company relies more on debt than equity. This ratio should be compared against industry standards to determine if Amicus Therapeutics, Inc. (FOLD)'s leverage is typical for its sector.

Recent financial activities, such as debt issuances, credit ratings, or refinancing, significantly impact Amicus Therapeutics, Inc. (FOLD)'s financial health. For example, a debt issuance might provide capital for expansion or research, but it also increases the company's debt burden. Credit ratings from agencies like Moody's or Standard & Poor's reflect the company's creditworthiness, influencing borrowing costs and investor confidence.

Balancing debt and equity is crucial for sustainable growth. While debt can provide necessary funds for expansion and operations, excessive debt can lead to financial instability. Equity funding, on the other hand, does not require repayment but can dilute existing shareholders' ownership. Amicus Therapeutics, Inc. (FOLD)'s approach to balancing these financing methods reflects its overall financial strategy and risk management.

For a deeper dive into Amicus Therapeutics, Inc. (FOLD)'s financial health, check out: Breaking Down Amicus Therapeutics, Inc. (FOLD) Financial Health: Key Insights for Investors

Amicus Therapeutics, Inc. (FOLD) Liquidity and Solvency

Assessing Amicus Therapeutics, Inc. (FOLD)'s financial health requires a close look at its liquidity and solvency. Liquidity refers to the company's ability to meet its short-term obligations, while solvency concerns its ability to meet long-term obligations. Both are vital for investors to gauge the stability and risk associated with the stock.

Liquidity Positions: Current and Quick Ratios

The current and quick ratios are key indicators of a company's liquidity. These ratios provide insight into whether a company possesses enough liquid assets to cover its short-term liabilities.

• Current Ratio: This is calculated by dividing current assets by current liabilities. A current ratio of around 1.5 to 2.0 is generally considered healthy, suggesting the company has enough assets to cover its short-term liabilities.
• Quick Ratio: Also known as the acid-test ratio, this is calculated by subtracting inventories from current assets and then dividing by current liabilities. It provides a more conservative view of liquidity by excluding inventories, which may not be easily convertible to cash. A quick ratio of 1.0 or higher is often preferred.

For Amicus Therapeutics, Inc. (FOLD), analyzing these ratios involves comparing their current values against industry benchmarks and historical data to identify trends and potential areas of concern. For example, a declining current ratio might signal potential liquidity issues.

Analysis of Working Capital Trends

Working capital, which is the difference between a company’s current assets and current liabilities, is another vital measure of liquidity. Monitoring the trends in working capital can reveal how effectively Amicus Therapeutics, Inc. (FOLD) manages its short-term assets and liabilities.

A positive working capital balance indicates that a company has enough short-term assets to cover its short-term liabilities. Conversely, negative working capital might indicate liquidity problems. Consistent increases in working capital usually suggest improving liquidity, while decreases might raise concerns.

Cash Flow Statements Overview

An overview of cash flow statements is crucial for understanding the sources and uses of cash within Amicus Therapeutics, Inc. (FOLD). The cash flow statement is divided into three main sections:

• Operating Activities: This section shows the cash generated or used from the company's core business operations. Positive cash flow from operations is a good sign, indicating the company is generating enough cash from its products or services.
• Investing Activities: This includes cash flow from the purchase and sale of long-term assets, such as property, plant, and equipment (PP&E). These activities can consume cash when the company is investing in growth or generate cash when assets are sold.
• Financing Activities: This section includes cash flow from debt, equity, and dividends. It shows how the company is funding its operations and returning capital to shareholders.

Analyzing these cash flow trends helps investors understand how Amicus Therapeutics, Inc. (FOLD) manages its cash and where the company is investing its resources. For example, a company that consistently generates positive cash flow from operations is generally considered financially healthy.

Potential Liquidity Concerns or Strengths

Investors should be aware of any potential liquidity concerns or strengths when evaluating Amicus Therapeutics, Inc. (FOLD). Here are some factors to consider:

• Strengths: High cash reserves, consistent positive cash flow from operations, and a healthy current ratio can be indicators of strong liquidity.
• Concerns: Declining cash reserves, negative cash flow from operations, increasing debt levels, and a low current ratio may signal potential liquidity problems.

Careful analysis of these elements provides a comprehensive view of Amicus Therapeutics, Inc. (FOLD)'s financial liquidity, helping investors make informed decisions.

For more insights into the investors of Amicus Therapeutics, Inc. (FOLD), check out: Exploring Amicus Therapeutics, Inc. (FOLD) Investor Profile: Who’s Buying and Why?

Amicus Therapeutics, Inc. (FOLD) Valuation Analysis

Determining whether Amicus Therapeutics, Inc. (FOLD) is overvalued or undervalued requires a multifaceted approach, incorporating key financial ratios, stock performance analysis, and analyst opinions. Let's delve into these aspects to provide a clearer picture for investors.

When evaluating valuation, several key ratios offer insights:

• Price-to-Earnings (P/E) Ratio: As Amicus Therapeutics does not currently have positive earnings, the P/E ratio is not applicable.
• Price-to-Book (P/B) Ratio: Examining the P/B ratio can provide insight into how the market values the company's net assets.
• Enterprise Value-to-EBITDA (EV/EBITDA): This ratio compares the total value of the company to its earnings before interest, taxes, depreciation, and amortization. This can be particularly useful for companies with significant debt or capital expenditures.

Analyzing Amicus Therapeutics' stock price trends over the past year offers crucial context. As of April 20, 2025, examining the stock's performance reveals:

Amicus Therapeutics does not currently offer a dividend, so dividend yield and payout ratios are not applicable.

Analyst consensus provides a summarized view of professional opinions on the stock:

• Buy Rating: Indicates analysts believe the stock is likely to outperform its peers.
• Hold Rating: Suggests analysts recommend maintaining current positions.
• Sell Rating: Implies analysts foresee underperformance and advise selling the stock.

For a deeper understanding of who is investing in Amicus Therapeutics, Inc. (FOLD) and their motivations, explore: Exploring Amicus Therapeutics, Inc. (FOLD) Investor Profile: Who’s Buying and Why?

Amicus Therapeutics, Inc. (FOLD) Risk Factors

Amicus Therapeutics, Inc. (FOLD) faces a variety of risks that could significantly impact its financial health. These risks span internal operational challenges and external market dynamics, demanding close attention from investors.

Industry Competition: The biopharmaceutical industry is intensely competitive. Amicus faces competition from established pharmaceutical companies and other biotech firms, some with greater financial and research resources. Competitors are working on similar treatments, which could reduce Amicus's market share if those treatments prove more effective or are brought to market first.

Regulatory Changes: The development, manufacturing, and marketing of Amicus's products are subject to extensive regulation by government authorities in the U.S. and abroad. Changes in these regulations, such as those related to clinical trial requirements, manufacturing standards, or marketing approvals, could increase costs, delay product launches, or limit the commercial potential of their products.

Market Conditions: Economic downturns, changes in healthcare policies, or shifts in market preferences can affect the demand for Amicus's therapies. Uncertainty in the healthcare landscape can lead to pricing pressures and reduced access to medications, impacting revenue.

Operational Risks:

• Manufacturing Challenges: Producing therapies is complex. Any disruptions in manufacturing, whether due to equipment failures, contamination, or supply chain issues, can lead to product shortages and lost revenue.
• Clinical Trial Outcomes: The success of Amicus depends on positive results from clinical trials. Unexpected adverse events or failure to meet trial endpoints could halt development programs and negatively affect investor confidence.
• Commercialization Risks: Successfully launching and selling therapies is crucial. Factors such as market acceptance, pricing, reimbursement policies, and competition can affect sales.

Financial Risks:

• Dependence on Key Products: A significant portion of Amicus's revenue may be concentrated in a small number of products. Poor performance of these key products could severely affect financial results.
• Funding and Capital Requirements: Developing and commercializing drugs requires substantial capital. Amicus may need to raise additional funds through debt or equity offerings, which could dilute existing shareholders' ownership or increase debt burden.
• Intellectual Property Protection: Amicus's success depends on protecting its intellectual property. Challenges to patents or the emergence of generic competition could erode market exclusivity and reduce profitability.

Strategic Risks:

• Reliance on Partnerships: Amicus may rely on collaborations and partnerships to develop and commercialize its products. The failure of these partnerships or disputes with partners could delay or disrupt their plans.
• Acquisition and Integration Risks: If Amicus pursues acquisitions, integrating acquired companies or technologies could be challenging and may not yield the expected benefits.

Mitigation strategies and plans often involve diversifying product pipelines, securing robust intellectual property rights, establishing strong relationships with regulatory agencies, and maintaining financial discipline. However, the specific details of these strategies are subject to change based on evolving circumstances and competitive pressures.

Here's a look at potential financial risks based on the company's recent performance:

To gain further insights into Amicus Therapeutics, Inc. (FOLD), consider exploring their Mission Statement, Vision, & Core Values of Amicus Therapeutics, Inc. (FOLD).

Amicus Therapeutics, Inc. (FOLD) Growth Opportunities

Amicus Therapeutics, Inc. (FOLD) is poised for future growth, driven by several key factors. These include product innovations, strategic market expansions, key partnerships, and the company's competitive advantages.

Here's a detailed look at these growth drivers:

• Product Innovations: Amicus Therapeutics focuses on developing novel therapies for rare diseases. Continued success in research and development is crucial for introducing new products to the market.
• Market Expansions: Expanding into new geographic markets and patient populations can significantly boost revenue.
• Strategic Initiatives or Partnerships: Collaborations with other pharmaceutical companies or research institutions can accelerate drug development and market access.
• Competitive Advantages: Proprietary technologies, strong patent protection, and established relationships with key opinion leaders provide a competitive edge.

To get a clearer picture of Amicus Therapeutics' potential, it's helpful to consider future revenue growth projections and earnings estimates. While specific figures can fluctuate based on various market conditions and company performance, analysts' consensus estimates offer a reasonable benchmark. Keep in mind that these are projections and not guarantees.

Here’s an overview of potential strategic initiatives and partnerships that could drive future growth for Amicus Therapeutics:

• New Product Launches: Successful launches of new therapies in the pipeline can significantly increase revenue.
• Expanded Indications: Gaining approval for existing therapies to treat additional conditions can broaden the patient base and drive sales.
• Geographic Expansion: Entering new markets, particularly in emerging economies, can unlock new revenue streams.
• Strategic Collaborations: Partnering with other companies to co-develop or co-market therapies can leverage resources and expertise.

Amicus Therapeutics holds several competitive advantages that position it for sustained growth:

• Focus on Rare Diseases: Specializing in rare diseases allows Amicus to address unmet medical needs and benefit from orphan drug designations, which provide market exclusivity and other incentives.
• Proprietary Technology: The company’s innovative technology platforms enable the development of novel therapies with improved efficacy and safety profiles.
• Strong Intellectual Property: A robust patent portfolio protects Amicus’s products and technologies from competition.
• Experienced Management Team: A skilled leadership team with a track record of success in the pharmaceutical industry guides the company’s strategic direction.

For further insights into the company's investor profile, explore: Exploring Amicus Therapeutics, Inc. (FOLD) Investor Profile: Who’s Buying and Why?